Glenmark Pharmaceuticals Ltd. Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹2192Market Cap
₹ 61,858 Cr.Stock P/E
21.0ROE
30.5 %RSI
35.13Trend
BearishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
Glenmark Pharmaceuticals Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest Glenmark Pharmaceuticals Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the Glenmark Pharmaceuticals Ltd share price chart currently indicates a Bearish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 2192 |
| RSI (14) | 35.13 |
| 50 DMA | 2234.36 |
| 200 DMA | 2093.53 |
| Trend | Bearish |
| A/D Rating | D |
| RS Rating | 50 |
| EPS Rating | 50 |
| TI65 | 0.98 |
| TI65 Trend | Neutral |
Pivot Points Analysis
Daily pivot points for Glenmark Pharmaceuticals Ltd. calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹2300 |
| R2 | ₹2274.4 |
| R1 | ₹2233.2 |
| PP | ₹2207.6 |
| S1 | ₹2166.4 |
| S2 | ₹2140.8 |
| S3 | ₹2099.6 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 61,858 Cr. |
| Current Price | ₹ 2,192 |
| High / Low | ₹ 2,474 / 1,793 |
| Stock P/E | 21.0 |
| Book Value | ₹ 372 |
| Dividend Yield | 0.11 % |
| ROCE | 39.8 % |
| ROE | 30.5 % |
| Face Value | ₹ 1.00 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 3,001 | -403 | 13% |
| Jun 2023 | 3,036 | 173 | 14% |
| Sep 2023 | 3,207 | -62 | 14% |
| Dec 2023 | 2,507 | -331 | -8% |
| Mar 2024 | 3,063 | -1,214 | 16% |
| Jun 2024 | 3,244 | 340 | 18% |
| Sep 2024 | 3,434 | 354 | 18% |
| Dec 2024 | 3,388 | 348 | 18% |
| Mar 2025 | 3,256 | 4 | 17% |
| Jun 2025 | 3,264 | 47 | 18% |
| Sep 2025 | 6,047 | 610 | 39% |
| Dec 2025 | 3,901 | 403 | 22% |
| Mar 2026 | 3,771 | 301 | 20% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 46.50% |
| FIIs | 34.78% |
| DIIs | 6.02% |
| Government | 0.00% |
| Public | 12.69% |
| No. of Shareholders | 88,103 |
Pros and Cons
Pros
- Healthy return on equity of 30.5% indicating strong capital allocation efficiency.
Cons
- Primary trend direction remains weak, stuck underneath major defensive supply barriers.
Related NSE Stocks
Cemindia Projects Ltd.
View Share Price Analysis →ITC Ltd.
View Share Price Analysis →Vardhman Textiles Ltd.
View Share Price Analysis →Asahi India Glass Ltd.
View Share Price Analysis →Fertilisers and Chemicals Travancore Ltd.
View Share Price Analysis →Mangalore Refinery & Petrochemicals Ltd.
View Share Price Analysis →Welspun Corp Ltd.
View Share Price Analysis →Star Health and Allied Insurance Company Ltd.
View Share Price Analysis →Elgi Equipments Ltd.
View Share Price Analysis →Motherson Sumi Wiring India Ltd.
View Share Price Analysis →eClerx Services Ltd.
View Share Price Analysis →Vedanta Ltd.
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for Glenmark Pharmaceuticals Ltd share?
Based on the latest closing data, the technical momentum for Glenmark Pharmaceuticals Ltd is currently evaluated as Bearish. The stock is exhibiting an RSI (14) of 35.13, indicating it is trading in a neutral balanced zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (2234.36) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for Glenmark Pharmaceuticals Ltd?
According to Classic Pivot Point methodologies, the core trading floor for Glenmark Pharmaceuticals Ltd today centers at a Pivot Point (PP) of ₹2207.6. Upside resistance challenges are calculated at R1: ₹2233.2, R2: ₹2274.4, and R3: ₹2300. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹2166.4, S2: ₹2140.8, and S3: ₹2099.6.
How does the fundamental ROE and P/E ratio look for Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd is currently trading with a valuation metrics context of a Stock P/E of 21.0, against a core structural efficiency Return on Equity (ROE) standing at 30.5 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 50, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell Glenmark Pharmaceuticals Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Chronic Downtrend / Potential Value Trap (Neutral / Avoid). Glenmark Pharmaceuti... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of D, a Relative Strength (RS) ranking of 50, and long-term trend backing from the TI65 indicator (Neutral pattern).